focus -WSS

focus

author：focus 2025-09-29 01:39:03 - browse：256

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： First Opinion Podcast: What happens when kids become caregivers?

Wikipedia

hotspot

WSS

Dark money group runs ads on China biotech bill

Startling documents reveal new facets of Sacklers' opioid empire

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

A Q&A with Aletha Maybank, AMA’s chief health equity officer

knowledge

focus

hotspot

Hollywood unions extend contract negotiations for actors

Covid isolation guidance eased by the CDC

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lab trade group sues FDA to halt regulation of lab

Malaria cases in Florida and Texas: Here’s what you need to know

Do more moles mean more problems? Not so, says new study

Affirmative action in medical school literally saved lives

How to fix the rural physician shortage in the U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

hotspot

Akili, maker of video game for ADHD, to be acquired for 34 million

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Lab trade group sues FDA to halt regulation of lab

Health insurers say they are turning to AI to cut costs, improve care

Heat waves linked to early deliveries, preterm births in new study

Insmed lung disease drug hits target in key Phase 3 trial

Wikipedia

explore

hotspot

explore